OBT076

DRUG2 trials

Sponsors

Oxford Biotherapeutics Limited, Groupe Oncologie Radiotherapie Tete et Cou

Conditions

Adenoid Cystic Carcinoma of the Head and NeckCD205+ve recurrent and/or metastatic tumor types including but not limited to gastric cancerNSCLCendometrial or ovarian cancer. Other tumor types may be added as more data become available.

Phase 1

Study of OBT076 Associated or Not in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma of the Head and Neck

TerminatedNCT05930951

Groupe Oncologie Radiotherapie Tete et CouAdenoid Cystic Carcinoma of the Head and Neck

Start: 2023-11-29End: 2024-10-09Updated: 2025-05-09

A Phase I/Ib, open-label, dose finding study to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of OBT076, a CD205-directed antibody-drug conjugate, in recurrent and/or metastatic CD205-positive solid tumors

RecruitingCTIS2024-511884-27-00

Oxford Biotherapeutics LimitedCD205+ve recurrent and/or metastatic tumor types including but not limited to gastric cancer, endometrial or ovarian cancer. Other tumor types may be added as more data become available., NSCLC

Start: 2022-11-09Target: 180Updated: 2025-10-03